Accessibility to biologics and its impact on disease activity and quality of life in patients with rheumatoid arthritis
- PDF / 432,589 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 28 Downloads / 170 Views
ORIGINAL ARTICLE
Accessibility to biologics and its impact on disease activity and quality of life in patients with rheumatoid arthritis in Kuwait Adeeba Al-Herz 1 & Khuloud Saleh 2 & Adel Al-Awadhi 3 & Waleed Al-Kandari 2 & Eman Hasan 1 & Aqeel Ghanem 4 & Mohammed Hussain 1 & Yaser Ali 4 & Ebrahim Nahar 4 & Ahmad Alenizi 5 & Sawsan Hayat 4 & Fatemah Abutiban 5 & Ali Aldei 1 & Hebah Alhajeri 4 & Naser Alhadhood 2 & Husain Bahbahani 2 & Hoda Tarakmeh 4 & Khaled Mokaddem 1 & Ahmad Khadrawy 2 & Ammad Fazal 2 & Agaz Zaman 4 & Ghada Mazloum 4 & Youssef Bartella 1 & Sally Hamed 1 & Ramia Alsouk 5 & Ahmed Al-Saber 6 & Kuwait Registry for Rheumatic Diseases (KRRD) Received: 31 May 2020 / Revised: 13 September 2020 / Accepted: 5 October 2020 # The Author(s) 2020
Abstract Objective Biologics are indicated in rheumatoid arthritis (RA) in case of persistent high disease activity despite conventional disease-modifying anti-rheumatic drugs (cDMARDs) or patients with contraindications to cDMARDs or poor prognostic factors. The purpose of this study was to compare the prescription rates of biologics in Kuwaiti and non-Kuwaiti patients and to assess whether this had an impact on disease activity and quality of life in RA patients. Methods Data were extracted from the Kuwait Registry for Rheumatic Diseases. Adult patients who satisfied the ACR classification criteria for RA from four major hospitals in Kuwait were evaluated from February 2013 through May 2018. The treatment agents, disease activity, and quality of life of Kuwaiti patients were compared with non-Kuwaiti patients. Results A total of 1651 RA patients were included; 806 (48.8%) were Kuwaiti patients. Among Kuwaiti patients, 62.5% were on biologic drugs in comparison with 14% of non-Kuwaiti patients. In comparison with non-Kuwaiti patients, Kuwaiti patients had significantly lower numbers of swollen joints (p < 0.001) and disease activity score-28 scores (p = 0.02) and less steroid use (p < 0.001) yet a significantly higher health assessment questionnaire-disability index (p < 0.001). Regression analysis showed that DAS-28 scores were significantly associated with the treatment type (p < 0.001) and that nationality was significantly predictive of the treatment type (p < 0.001). Conclusion In the setting of easy accessibility to treatment for Kuwaiti patients, biologics were prescribed by rheumatologists at a higher rate than for non-Kuwaitis. This may explain the lower disease activity and the lower rate of steroid use in Kuwaiti patients than non-Kuwaitis. Key points • Significant discrepancies in the rates of prescribing biologic therapies between KP and NKP in Kuwait were observed. • Several treatment outcomes were significantly better in the KP group than in the NKP group even after adjustment of confounding factors. • The poor access to biologic therapies was suggested to limit the effectiveness of RA treatments in the NKP group. Keywords Biologics . DAS-28 . Kuwait . Rheumatoid arthritis
* Adeeba Al-Herz [email protected]
3
Department of Medicine, Faculty
Data Loading...
